These results indicate that CD11b+ cells, including antigen-presenting cells, are increased in the dLN of treated mice, while the CD4+/CD8+ T cell ratio is skewed to favor CD8+ T cells in the dLN and spleen, which corroborate the tumor-specific, CD8+ T cell responses that we previously found to be essential for efficacy. This evidence concerns the gene CD8A and neoplasm.